SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+23.56%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$348M
AUM Growth
–
Cap. Flow
+$348M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
42.53%
Holding
63
New
55
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Roivant Sciences
ROIV
|
$24.4M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$23.7M |
| 3 |
Arcellx
ACLX
|
$17.4M |
| 4 |
Merus
MRUS
|
$13.8M |
| 5 |
Immunovant
IMVT
|
$13.6M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 98.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Roivant Sciences
ROIV
$8.15B
| $24.4M | 6.5% |
+2,169,116
| New | +$24.4M |
|
|
2
Syndax Pharmaceuticals
SNDX
$1.41B
| $23.7M | 6.31% |
+1,094,494
| New | +$23.7M |
|
|
3
Arcellx
ACLX
$3.85B
| $17.4M | 4.64% |
+313,604
| New | +$17.4M |
|
|
4
Merus
MRUS
$4.98B
| $13.8M | 3.68% |
+501,806
| New | +$13.8M |
|
|
5
Immunovant
IMVT
$2.56B
| $13.6M | 3.62% |
+322,015
| New | +$13.6M |
|
6
Amicus Therapeutics
FOLD
$2.34B
| $12.2M | 3.27% |
+862,815
| New | +$12.2M |
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $11.8M | 3.14% |
+513,681
| New | +$11.8M |
|
8
Immatics
IMTX
$619M
| $10.7M | 2.87% |
+1,020,214
| New | +$10.7M |
|
9
BridgeBio Pharma
BBIO
$9.89B
| $10.3M | 2.74% |
+253,948
| New | +$10.3M |
|
10
Cabaletta Bio
CABA
$133M
| $10.2M | 2.73% |
+450,706
| New | +$10.2M |
|
11
MoonLake Immunotherapeutics
MLTX
$3.54B
| $10.1M | 2.7% |
+167,851
| New | +$10.1M |
|
12
Merck
MRK
$210B
| $9.7M | 2.59% |
+89,016
| New | +$9.7M |
|
13
Johnson & Johnson
JNJ
$427B
| $9.56M | 2.55% |
+61,011
| New | +$9.56M |
|
14
Crinetics Pharmaceuticals
CRNX
$2.92B
| $8.88M | 2.37% |
+249,575
| New | +$8.88M |
|
15
Eli Lilly
LLY
$657B
| $8.78M | 2.34% |
+15,067
| New | +$8.78M |
|
16
VistaGen Therapeutics
VTGN
$102M
| $8.76M | 2.34% |
+1,790,182
| New | +$8.76M |
|
17
Arcutis Biotherapeutics
ARQT
$1.86B
| $8.38M | 2.24% |
+2,594,536
| New | +$8.38M |
|
18
Spyre Therapeutics
SYRE
$996M
| $8.15M | 2.17% |
+378,766
| New | +$8.15M |
|
19
Disc Medicine
IRON
$2.07B
| $7.24M | 1.93% |
+125,429
| New | +$7.24M |
|
20
Lantheus
LNTH
$3.73B
| $6.75M | 1.8% |
+108,911
| New | +$6.75M |
|
21
Legend Biotech
LEGN
$6.41B
| $6.3M | 1.68% |
+104,650
| New | +$6.3M |
|
22
Astria Therapeutics
ATXS
$349M
| $6.16M | 1.64% |
+856,952
| New | +$6.16M |
|
23
Insmed
INSM
$28.8B
| $5.38M | 1.44% |
+173,579
| New | +$5.38M |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $5.18M | 1.38% |
+423,174
| New | +$5.18M |
|
25
Biohaven
BHVN
$1.63B
| $4.77M | 1.27% |
+111,354
| New | +$4.77M |
|